



NEWS RELEASE

CRINETICS PHARMACEUTICALS TO PARTICIPATE IN DECEMBER INVESTOR CONFERENCES

2020-11-23

San Diego, CA, November 23, 2020 – **Crinetics Pharmaceuticals** (Nasdaq:CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:

Evercore ISI 3rd Annual HealthCONx Conference

Date: Thursday, December 3rd, 2020

Time: 1:00-1:45 pm ET in Track 1

Panel: Easy Pills to Swallow: Oral Drugs for Large Endo Markets

Presenter: Dr. Scott Struthers, Founder & CEO

Piper Sandler's 32nd Annual Healthcare Conference

Date: Tuesday – Thursday, December 1st-3rd, 2020

Time: On demand

Presenter: **Dr. Scott Struthers**, Founder & CEO, and **Dr. Alan Krasner**, Chief Medical Officer

Webcast: Pre-recorded fireside chats will be available for viewing until the 3rd here **32nd annual Piper Sandler Healthcare Conference** and the Piper Sandler conference website.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's



lead product candidate, **paltusotine (formerly CRN00808)**, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing **CRN04777**, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the **treatment of Cushing's disease, congenital adrenal hyperplasia** and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit **crinetics.com**.

Contact:

Marc Wilson

Chief Financial Officer

IR@crinetics.com

(858) 450-6464

Investors / Media:

Corey Davis

LifeSci Advisors

cdavis@lifesciadvisors.com

(212)-915-2577

Aline Sherwood

Scienta Communications

asherwood@scientapr.com

(858) 450-6464

Source: Crinetics Pharmaceuticals, Inc.